Skip to content

Study · Non-randomized trial · n = 21 · 2006

9 results

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, Ferdeghini M, Pederzoli P, Scarpa A, Falconi M

Endocrine-related cancer1 Dec 2006Cited by 71 (Europe PMC)

PMID17158766 (opens in a new tab)DOI10.1677/erc.1.01200 (opens in a new tab)PepBankPUB-17158766
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In advanced NF-PEC treated with octreotide, eight patients (38%) had stable disease after median follow-up of 49.5 months.

    In plain wordsIn advanced pancreatic endocrine cancer treated with octreotide, 38% had stable disease during follow-up.

    Peptide
    Octreotide
    Outcome
    Not applicableStable disease
    Study

    n = 21

    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Measurements

    Patients with stable disease
    8 patients
    single-arm octreotide LAR, n=21
    Patients with stable disease
    38%
    single-arm octreotide LAR
    Median follow-up
    49.5 months
    stable-disease patients

    Source sentences

    Summary
    Eight patients (38%) had stable disease (SD) after a median follow-up of 49.5 months.
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  2. 02HumanNon-randomized trialEfficacy outcome

    In advanced NF-PEC treated with octreotide, thirteen patients (62%) progressed after a median of 18 months.

    In plain wordsIn advanced pancreatic endocrine cancer treated with octreotide, 62% developed progression.

    Peptide
    Octreotide
    Outcome
    Not applicableDisease progression
    Study

    n = 21

    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Measurements

    Patients with progression
    13 patients
    single-arm octreotide LAR, n=21
    Patients with progression
    62%
    single-arm octreotide LAR
    Median time to progression
    18 months
    progressing patients

    Source sentences

    Summary
    Thirteen patients (62%) developed progression after a median of 18 months.
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  3. 03HumanObservational studyEfficacy outcome

    In octreotide-treated NF-PEC, progression was linked to proliferative index at least 5% (P=0.016).

    In plain wordsIn octreotide-treated pancreatic endocrine cancer, progression was linked to a higher proliferative index.

    Peptide
    Octreotide
    Outcome
    IncreaseProgression association with proliferative index
    Study

    n = 21

    Comparator
    Lower proliferative index
    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Measurements

    P value, correlation of progression with proliferative index >=5%
    0.016 P
    octreotide-treated NF-PEC, n=21

    Source sentences

    Summary
    Tumour progression correlated with a proliferative index>or=5% (P=0.016), weight loss (P=0.006) and absence of abdominal pain (P=0.003) at diagnosis.
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  4. 04HumanObservational studyEfficacy outcome

    In octreotide-treated NF-PEC, progression was linked to weight loss at diagnosis (P=0.006).

    In plain wordsIn octreotide-treated pancreatic endocrine cancer, progression was linked to weight loss at diagnosis.

    Peptide
    Octreotide
    Outcome
    IncreaseProgression association with weight loss
    Study

    n = 21

    Comparator
    No weight loss at diagnosis
    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Measurements

    P value, correlation of progression with weight loss
    0.006 P
    octreotide-treated NF-PEC, n=21

    Source sentences

    Summary
    Tumour progression correlated with a proliferative index>or=5% (P=0.016), weight loss (P=0.006) and absence of abdominal pain (P=0.003) at diagnosis.
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  5. 05HumanObservational studyEfficacy outcome

    In octreotide-treated NF-PEC, progression was linked to absence of abdominal pain at diagnosis (P=0.003).

    In plain wordsIn octreotide-treated pancreatic endocrine cancer, progression was linked to absence of abdominal pain at diagnosis.

    Peptide
    Octreotide
    Outcome
    IncreaseProgression association with absence of abdominal pain
    Study

    n = 21

    Comparator
    Abdominal pain at diagnosis
    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Measurements

    P value, correlation of progression with absence of abdominal pain
    0.003 P
    octreotide-treated NF-PEC, n=21

    Source sentences

    Summary
    Tumour progression correlated with a proliferative index>or=5% (P=0.016), weight loss (P=0.006) and absence of abdominal pain (P=0.003) at diagnosis.
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  6. 06HumanObservational studyEfficacy outcome

    In octreotide-treated NF-PEC, age, gender, resection, tumor site, size and liver metastasis lacked significant correlations with progression.

    In plain wordsIn octreotide-treated pancreatic endocrine cancer, the other listed clinical and tumor features were not significantly linked to progression.

    Peptide
    Octreotide
    Outcome
    No significant changeOther clinical and pathological predictors
    Study

    n = 21

    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Source sentences

    Summary
    Other clinical (age, gender and primary tumour resection) or pathological parameters (site, size and liver metastasis) lacked significant correlation with tumour progression.
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  7. 07HumanObservational studyEfficacy outcome

    In octreotide-treated NF-PEC, SSTR2 mRNA did not differ between stable and progressing tumors.

    In plain wordsIn octreotide-treated pancreatic endocrine cancer, SSTR2 gene activity was similar in stable and progressing tumors.

    Peptide
    Octreotide
    Outcome
    No significant changeSSTR2 mRNA
    Study

    n = 12

    Comparator
    Progressing tumors
    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No difference in the amount of SSTR2 mRNA and protein or SSTR5 mRNA was found between tumours that were stable (n=5) and seven tumours that progressed (n=7).
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  8. 08HumanObservational studyEfficacy outcome

    In octreotide-treated NF-PEC, SSTR2 protein did not differ between stable and progressing tumors.

    In plain wordsIn octreotide-treated pancreatic endocrine cancer, SSTR2 protein was similar in stable and progressing tumors.

    Peptide
    Octreotide
    Outcome
    No significant changeSSTR2 protein
    Study

    n = 12

    Comparator
    Progressing tumors
    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No difference in the amount of SSTR2 mRNA and protein or SSTR5 mRNA was found between tumours that were stable (n=5) and seven tumours that progressed (n=7).
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.
  9. 09HumanObservational studyEfficacy outcome

    In octreotide-treated NF-PEC, SSTR5 mRNA did not differ between stable and progressing tumors.

    In plain wordsIn octreotide-treated pancreatic endocrine cancer, SSTR5 gene activity was similar in stable and progressing tumors.

    Peptide
    Octreotide
    Outcome
    No significant changeSSTR5 mRNA
    Study

    n = 12

    Comparator
    Progressing tumors
    Outcome group
    Tumor growth · Cancer
    Studied dose
    20 mg long-acting release · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No difference in the amount of SSTR2 mRNA and protein or SSTR5 mRNA was found between tumours that were stable (n=5) and seven tumours that progressed (n=7).
    2 context sentences
    Summary · context
    We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy.
    Summary · context
    Twenty-one consecutive patients with octreoscan-positive advanced-stage well-differentiated NF-PEC were treated with long-acting release octreotide 20 mg i.m. at diagnosis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.